Name: Fingolimod (FTY720)
Price: 196.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Fingolimod is a mechanistically novel, orally bioavailable therapy for multiple sclerosis (MS) [1].
    Fingolimod is a FDA approved drug for Multiple sclerosis treatment. It is a folk medicine emerged from Fungi. Fingolimod was firstly found to be a therapeutic agent in organ transplantation. Then Fingolimod was found to have similar structure with natural sphingosine and interact with S1P1, S1P4, S1P5 and S1P3 receptors as high affinity agonist with EC50 values of 0.3-3.1 nM. It plays the role in MS treatment through receptor-mediated actions both on the immune system and in the CNS. Fingolimod can prevent normal lymphocyte egress and reduce the infiltration of autoaggressive lymphocytes into the CNS [1, 2].
    
    [1] Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discovery medicine, 2011, 12 (64): 213.
    [2] Chun J, Hartung H P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clinical neuropharmacology, 2010, 33 (2): 91.
- Properties
  - Categories
    
    S1P receptors agonist
    
    Alternative Name
    
    Gilenia; FTY 720; FTY-720; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride
    
    CAS Number
    
    162359-56-0
    
    Molecular Formula
    
    C19H34ClNO2
    
    Molecular Weight
    
    343.94
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥15.3 mg/mL in EtOH; ≥17.2 mg/mL in DMSO; ≥31.3 mg/mL in H2O with ultrasonic
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
    
    * For Research Use Only